| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Basic Study |
| Article Title |
Genipin relieves diabetic retinopathy by down-regulation of advanced glycation end products via the mitochondrial metabolism related signaling pathway
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ke-Xin Sun, Yan-Yi Chen, Zhen Li, Shi-Jie Zheng, Wen-Juan Wan, Yan Ji and Ke Hu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China (General Program) |
81870650 |
| National Natural Science Foundation of China (General Program) |
81570832 |
| National Natural Science Foundation of China (General Program) |
81900885 |
| Science and Technology Program Chongqing |
2018GDRC008 and XKTS049 |
|
| Corresponding Author |
Ke Hu, Doctor, MD, Chief Doctor, Doctor, Doctor, Professor, Department of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. 42222@qq.com |
| Key Words |
Genipin; Human retinal microvascular endothelial cells; Angiogenesis; Vascularization; Secretogranin III; Diabetic retinopathy |
| Core Tip |
The formation of advanced glycation end products (AGEs) has been widely validated in pathological changes of diabetic retinopathy (DR). A new vital compound in Gardenia jasminoides Ellis fruit, genipin, can be used to treat DR and decrease AGEs. Genipin ameliorated AGEs-induced human retinal microvascular endothelial cell proliferation, apoptosis, energy metabolism, oxidative stress, and inflammatory injury, partially via the CHGA/UCP2/glucose transporter 1 pathway. Control of AGEs by intraocular injection of genipin may represent a strategy to prevent severe retinopathy and vision loss. Here, we confirmed the effectiveness of genipin to treat DR both in vivo and in vitro, and explored its related molecular mechanism. |
| Publish Date |
2023-09-13 12:15 |
| Citation |
Sun KX, Chen YY, Li Z, Zheng SJ, Wan WJ, Ji Y, Hu K. Genipin relieves diabetic retinopathy by down-regulation of advanced glycation end products via the mitochondrial metabolism related signaling pathway. World J Diabetes 2023; 14(9): 1349-1368 |
| URL |
https://www.wjgnet.com/1948-9358/full/v14/i9/1349.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v14.i9.1349 |
